Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DARATUMUMAB Cause Therapy partial responder? 189 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 189 reports of Therapy partial responder have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.7% of all adverse event reports for DARATUMUMAB.

189
Reports of Therapy partial responder with DARATUMUMAB
0.7%
of all DARATUMUMAB reports
29
Deaths
25
Hospitalizations

How Dangerous Is Therapy partial responder From DARATUMUMAB?

Of the 189 reports, 29 (15.3%) resulted in death, 25 (13.2%) required hospitalization, and 7 (3.7%) were considered life-threatening.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 189 reports have been filed with the FAERS database.

What Other Side Effects Does DARATUMUMAB Cause?

Plasma cell myeloma (2,980) Infusion related reaction (2,557) Off label use (2,494) Pneumonia (1,450) Neutropenia (1,351) Drug ineffective (1,110) Thrombocytopenia (1,089) Death (1,088) Pyrexia (1,032) Dyspnoea (996)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) PEMBROLIZUMAB (1,125) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670)

Which DARATUMUMAB Alternatives Have Lower Therapy partial responder Risk?

DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ DARATUMUMAB vs DARBEPOETIN ALFA DARATUMUMAB vs DARIDOREXANT DARATUMUMAB vs DARIFENACIN HYDROBROMIDE DARATUMUMAB vs DAROLUTAMIDE

Related Pages

DARATUMUMAB Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder DARATUMUMAB Demographics